Hoffmann-la Roche Inc.

Roche Glycart Ag

Boehringer Mannheim Gmbh

Genentech, Inc.

Abbvie Inc.

Engmab Sarl

Other

Roche Diagnostics Gmbh

Bristol-myers Squibb Compnay

Roche Diagnostics Operations, Inc.

Ono Pharmaceutical Co., Ltd.

Roche Sequencing Solutions, Inc.

F. Hoffmann-la Roche Ag

Roche Glyeart Ag

Ludwig-Maximilians-Universitat München

Christian Klein

Pablo Umana

Ekkehard Moessner

Ralf Hosse

Joerg Thomas Regula

Wolfgang Schaefer

Peter Bruenker

Marina Bacac

Sabine Imhof-Jung

Anne Freimoser-Grundschober

Claudia Ferrara Koller

Thomas U Hofer

Pablo Umaña

Ulrich Brinkmann

Michael Molhoj

Guy Georges

Stefan Seeber

Werner Scheuer

Hans-Georg Batz

Rupert Herrmann

Hubert Kettenberger

Petra Rueger

Hans-Peter Josel

Kay-Gunnar Stubenrauch

Klaus Kaluza

Erasmus Huber

Erhard Kopetzki

Ulrich Goepfert

Wayne J Fairbrother

Dieter Heindl

Tilman Schlothauer

Georg Fertig

Birgit Bossenmaier

Herbert Von Der Eltz

Joerg Moelleken

Lei Shi

Victor I Lyamichev

Herbert Harttig

Peng Wang

Andrew G Polson

Michael Schraeml

Alfred Mertens

Stefan Dengl

Jens Niewoehner

Uwe Kobold

Garry E Kiefer

Michael Gerg

Konrad Honold

Carola Ries

Oliver Ast

Juergen Michael Schanzer

Sandra Grau-Richards

Valeria G Nicolini

Maria Amann

Harald Duerr

Christina Claus

Christiane Neumann

Viktor Levitski

Anita Kavlie

Claudio Sustmann

Tanja Fauti

Stefan Klostermann

Remko Griep

Lydia Jasmin Hanisch

Inja Waldhauer

Tina Weinzierl

Deepak Sampath

Laurent Lariviere

Jens Fischer

Monika Baehner

Sebastian Fenn

Klaus-Peter Kuenkele

Gerhard Niederfellner

Valeria Lifke

Frank Herting

Ulrich Essig

Wolfgang Rollinger

Jigar Patel

Matthias Rueth

Eike Hoffmann

Huisheng Wang

Christa Hubner-Parajsz

Reiner Schlipfenbacher

Kathryn Elizabeth Packman

Rolf Lerch

Dieter Mangold

Josef Maier

Toshio Yoshizawa

Manfred Kubbies

Peter Sluka

Joerg Benz

Hendrik Knoetgen

Thomas Friess

Michael Tacke

Friederike Hesse

Alexander Haas

Rudolf Vogel

Hans-Joachim Guder

Johannes Auer

Wolfgang Knoll

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen and (b) a first and a second polypeptide that are linked to each other by a disulfide bond, characterized in that the first polypeptide comprises two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and in that the second polypeptide comprises only one ectodomain of said TNF ligand family member or a fragment thereof.

Methods of treating cancer by administering tumor necrosis factor (TNF) family ligand trimer-containing antigen-binding molecules

The present invention relates in particular to a cathepsin S inhibitor for use in a method for reducing or preventing the formation of anti-drug antibodies (ADA) against a therapeutic agent in a subject who is receiving a treatment with said therapeutic agent.

Use of a cathepsin s inhibitor against the formation of anti-drug antibodies

The invention relates to bispecific antibodies comprising a first antigen-binding site that specifically binds to PD1 and a second antigen-binding site that specifically binds to TIM3, in particular to bispecific antibodies, wherein the bispecific antibody binds to 5 TIM3 with a lower binding affinity when compared to the binding to PD1. The invention further relates to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for PD1 and TIM3

Herein are provided bispecific anti-human A-beta/human transferrin receptor antibodies and methods of using the same.

Bispecific anti-human A-beta/anti-human transferrin receptor antibodies

The present invention relates to a new cell-based assay for determining antigen expression in primary tumor samples. The method further relates to the determination of antigen and protease expression in primary tumor samples. The method allows robust determination of antigen and/or protease expression without the need to digest the tumor samples. The method further allows for selection of antibodies and for selection of protease-cleavable linkers for the treatment of tumors.

Methods to determine antibody activity in tumor samples

The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.

Trispecific antibodies specific for HER2 and a blood brain barrier receptor and methods of use

The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain. The invention also provides the production and use of T cells in a method for the treatment of particular diseases in conjunction with tumor-specific antibodies as well as pharmaceutical compositions/medicaments comprising T cells and/or therapeutic antibodies, wherein T cells are to be administered in combination with therapeutic-tumor targeting antibody/antibodies comprising a mutated Fc domain with reduced Fc receptor binding.

Antigen binding receptors specific for mutated Fc domains

The invention provides antibodies against Fibroblast Activation Protein (FAP) and methods of using the same.

Anti-FAP antibodies and methods of use

The present invention relates to combination therapies employing 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, in combination with HER-2 targeting agents, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.

Combination therapy with targeted 4-1BB (CD137) agonists

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one antigen binding domain capable of specific binding to Fibroblast Activation Protein (FAP) comprising FAP clone 212 or variants thereof, and (b) at least one antigen binding domain capable of specific binding to CD40, and to methods of producing these molecules and to methods of using the same.

Bispecific antigen binding molecules comprising anti-FAP clone 212

The invention relates to novel bispecific antigen binding molecules, comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) at least one moiety capable of specific binding to a costimulatory TNF receptor family member, and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Bispecific antibodies specific for OX40

The invention relates to novel bispecific antibodies consisting of two fusion polypeptides comprising two antigen binding domains capable of specific binding to a first target and one antigen binding domain capable of specific binding to a second target, and to methods of producing these molecules and to methods of using the same.

Bispecific 2+1 contorsbodies

The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.

Antibodies binding to CD3 and CD19

The invention relates to novel TNF family ligand trimer-containing antigen binding molecules comprising (a) at least one moiety capable of specific binding to a target cell antigen, (b) a polypeptide comprising three ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by peptide linkers and (c) a Fc domain composed of a first and a second subunit capable of stable association, and to methods of producing these molecules and to methods of using the same.

Antigen binding molecules comprising a trimeric TNF family ligand and encoding polynucleotides thereof

The present invention is directed to the combination therapy of an anti-CD20 antibody with a BTK inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with a type I anti-CD20 antibody or an afucosylated humanized B-Ly1 antibody and a BTK inhibitor.

Combination therapy of an anti CD20 antibody with a BTK inhibitor

Growing community of inventors

Bonstetten, Switzerland

Christian Klein